VC Catalog · venture ecosystem research library
VC Catalog home Beta

Company

Alderaan Biotechnology

Rocket Ship RatingBased on the data VC Catalog holds.

Rocket Ship Rating: 75 out of 100

  • Biotech & therapeutics
Business model
B2B
Open relationship map
Claim, correct or request removal

Record updated 28 September 2026

About

Alderaan Biotechnology develops antibodies directed against immune cells for the treatment of cancers. The first program is dedicated to the development of IL2-sparing, CD25-specific antibodies allowing Regulatory T cells (Tregs) depletion in tumours. The second program is focused on NK cell modulation using antibodies specific for CD160-TM, a new NK cell activating receptor.

Loading relationship preview

Cookies on VC Catalog

We use necessary cookies to run the site (sign-in, security, remembering this choice). With your permission we also use Google Analytics to understand how the site is used. Analytics cookies are set only if you accept all cookies. Privacy policy